Contact: Doug Dollemore(301)
“Although one must be cautiously optimistic when moving drugs from animals to humans, as the results are not always the same, these new drugs are remarkably effective in the animal studies, and appear to be well-tolerated”, says Mark Mattson, Ph.D., chief of the NIA’s Laboratory of Neurosciences. The study abstract will be available online at the Annals of Neurology website, http://www3.interscience.wiley.com/cgi-bin/issuetoc?ID=78504407 after the embargo lifts.
In the study, dopamine-producing nerve cells in mice treated with pifithrin-alpha (PFT), an experimental cancer treatment, and Z-1-117, a modified version of PFT, were more resistant to being killed by environmental toxins and pesticides, such as MPTP, iron, and rotenone. These toxins are suspected of increasing the risk of Parkinson’s disease in humans and can induce symptoms of the disease in rats and mice. The drugs also helped preserve motor function in mice exposed to these compounds. The investigators suspect the drugs work because they block the action of p53, a protein that may promote the death of dopamine-producing nerve cells.
The NIA team found that p53 kills these nerve cells by causing an increase in the permeability of the membranes surrounding mitochondria, the organelles in the cell that produce energy. This increased permeability causes the release of chemicals from mitochondria that destroy the cell. The same alterations in mitochondria are believed to occur in dying nerve cells in Alzheimer’s disease and in people who have had strokes. However, PFT and Z-1-117 prevented these mitochondrial alterations.
“Not only do these findings reveal a new avenue for treating people who have Parkinson’s disease, but they provide the opportunity to better understand how p53 kills nerve cells and whether this might also occur in other neurological diseases,” Dr. Mattson said. His lab is currently determining whether the p53 inhibitors might be effective in mouse models of Alzheimer’s disease and has found that PFT and Z-1-117 are effective in reducing nerve cell damage and improving functional recovery following a stroke in mice. If additional studies confirm that these drugs are safe and effective in animals, then they will likely be tested in humans.
Parkinson's disease occurs when nerve cells in a brain region called the substania nigra die or become impaired and can no longer produce dopamine. Without dopamine, individuals can develop tremor or trembling in hands, arms, legs, jaw, and face; rigidity or stiffness of the limbs and trunk; bradykinesia, or slowness of movement; and postural instability or impaired balance and coordination. Patients may also have difficulty walking, talking, or completing other simple tasks. The disease is both chronic and progressive. Parkinson's is not usually inherited, but incidence of the disease increases with age, with an average onset at about 60 years. It afflicts about 50,000 Americans annually.
The NIA leads the Federal effort supporting and conducting biomedical, clinical, social, and behavioral research on aging. This effort includes research into the causes and treatment of Alzheimer’s disease, Parkinson’s disease, stroke and other neurodegenerative disorders associated with age. Press releases, fact sheets, and other materials about aging and aging research can be viewed at the NIA’s general information Web site, www.nia.nih.gov.